FOR IMMEDIATE RELEASE: 2022/1/25

M3 to Acquire 3H Holdings and Three Other Group Companies~ Leading a next-generation clinical trial area leveraging largest patient recruitment panels ~M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3”below) has announced the acquisition of 3H Holdings (Headquarters: Tokyo, Japan; CEO: Sho Ando;
URL: https://3h-holdings.co.jp/ ), 3H Medi Solution (Headquarters: Tokyo, Japan; CEO: Sho Ando;
URL: https://3h-ms.co.jp/ ), 3H Clinical Trial (Headquarters: Tokyo, Japan; CEO: Hirotaka Takizawa;
URL: https://3h-ct.co.jp/ ) and its subsidiary 3H CTS (Headquarters: Tokyo, Japan; CEO: YoshinoriTakahashi; URL: https://3hcts.co.jp/; “3H Group” for these four companies below) as of February 1st,2022.
BackgroundM3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare
related information to its 300,000+ physician members in Japan, and offers marketing and clinical trialservices. Recent business expansions have been in areas such as AI diagnostic tool development,
genome diagnostics provision, and stroke rehabilitation centers, no longer limited to pharmaceuticalmarketing. “7P Projects” aim to integrate such businesses in order to provide holistic solutions for
multiple issues within individual therapeutic areas.
In the clinical trial field, M3 promotes the efficiency of clinical trials using the internet through its
subsidiary CROs(*1), SMOs(*2), and PROs(*3), including “Mr. Finder”, a clinical trial support service
that finds sites and patients to participate if clinical trials. In addition, Qlife, a PRO of the M3 Group,
has a 600,000 patient panel for clinical trials.
As a life science company that connects Human Health and Happiness, the 3H Group provides
one-stop services in the pharmaceutical and medical fields, from recruiting patients to participate intrials, conducting patient surveys, providing information, developing applications and systems, tosupporting new business development, by utilizing its world’s largest patient recruitment panel of910,000 members. By supporting drug discovery and drug development based on science and patient
centricity, and by realizing digital health transformation using the latest technology, the 3H Groupsolves the problems of patients and the medical field.
*1 CRO: Contract Research Organization*2 SMO: Site Management Organization*3 PRO: Patient Recruitment Organization

Expected synergies through this acquisitioni.

Streamline patient recruiting by utilizing the largest patient recruitment panel
This initiative will create a panel of more than 1.5 million combined members acrossthe M3 Group and the 3H Group. By further accelerating patient recruitment, it is now
possible to further promote the efficiency of clinical trials. As a result, 3H Group and M3
will develop a comprehensive evidence solution utilizing its 300,000 physicianmembership and the largest patient recruitment panel in Japan.

ii.

Further strengthen our position as a leading company in DCT (*4) support
In recent years, DCT, a new clinical trial method that does not rely on physicalvisits to medical institutions, has been attracting attention due to the increased
recognition of patient centricity and the use of digital technology in drug development. Asa pioneer and leader within this field, 3H Group and M3 have been providing DCT support
services to pharmaceutical companies. By leveraging the know-how and businessassets of both companies, 3H Group and M3 will contribute to the spread andinfrastructure development of clinical trials that are at the same level as the world's mostadvanced and with less patient burden.

iii.

Establish an ePRO (*5) platform by linking the contact points with medical institutions andpatients
The 3H Group has been working to improve the efficiency of obtaining case report
data from patients in clinical research by providing the ePRO application "P-guardian".
Through this initiative, 3H Group and M3 will build a platform that enables appropriate
communication between patients and medical professionals, by linking "P-guardian" withmedical institutions and patient contact points such as "M3 DigiKar Smart" and "M3DigiKar" developed by M3 Group.

iv.

Expand and add value to services through wide-ranging collaboration with clinical trials andclinical research related companies in the M3 Group
By collaborating in a wide range of businesses related to clinical trials and clinicalresearch, such as pharmaceutical affairs consulting companies, CROs or SMOs, ownedby the both groups, 3H Group and M3 will provide even more seamless support for drug
development from strategic planning to market launch and subsequent valueenhancement through evidence creation. In addition, in each process, 3H Group and M3
aims to expand and add value to services by utilizing the assets of both companies.

*4 DCT: Decentralized Clinical Trials; A clinical trial initiative to reduce the number of physical visitsof patients to a medical institution by using online or home visits.
*5 ePRO: electronic Patient Reported Outcome



Overview of each companyi.
3H Holdings
Established: 2018
Headquarters: Tokyo, Japan
URL: https://3h-holdings.co.jp/Representative Director and President: Sho AndoBusiness: Management of 3H Groupii.

3H Medi Solution
Established: 2009
Headquarters: Tokyo, Japan
URL: https://3h-ms.co.jp/
Representative Director and President: Sho AndoBusiness: Provision of clinical studies support, DCT support, and clinical trial applications andsystems

iii.

3H Clinical Trial
Established: 2005
Headquarters: Tokyo, Japan
URL: https://3h-ct.co.jp/
Representative Director and President: Hirotaka Takizawa
Business: Provision of patient recruitment service through “Seikatsu-Kojo WEB”, the largest
and most reputable clinical trial information website in Japaniv.

3H CTS
Established: 2014
Headquarters: Tokyo, Japan
URL: https://3hcts.co.jp/
Representative Director and President: Yoshinori Takahashi
Business: Site Management Organization